How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    1 Recommendations

    When open-heart surgery is high risk, and transcatheter valve repair is unsuitable

    1.1

    Transcatheter tricuspid valve implantation can be used in the NHS during the evidence generation period as an option to treat symptomatic severe tricuspid regurgitation when open surgical tricuspid valve repair or replacement is high risk, and transcatheter tricuspid valve repair is unsuitable. There must be enhanced informed consent and auditing of outcomes.

    When open-heart surgery is not high risk, or transcatheter valve repair is suitable

    1.2

    More research is needed on transcatheter tricuspid valve implantation to treat symptomatic severe tricuspid regurgitation before it can be used in the NHS when open surgical tricuspid valve repair or replacement is not high risk, or transcatheter tricuspid valve repair is suitable.

    1.3

    This procedure should only be done as part of formal research and a research ethics committee needs to have approved its use.

    What this means in practice

    When open-heart surgery is high risk, and transcatheter valve repair is unsuitable

    There are uncertainties around the safety and efficacy of this procedure. It can be used if needed while more evidence is generated.

    After this, this guidance will be reviewed and the recommendations may change.

    Healthcare professionals do not have to offer this procedure and should always discuss the available options with the person with tricuspid regurgitation before a joint decision is made.

    Hospital trusts will have their own policies on funding procedures and monitoring results. NHS England may also have policies on funding of procedures.

    Enhanced informed consent

    Because there are uncertainties about whether this procedure is safe and efficacious, there must be an emphasis on informed consent. Healthcare professionals must make sure that people (and their families and carers as appropriate) understand the uncertainty and lack of evidence around a procedure's safety and efficacy using NICE's advice on shared decision making and NICE's information for the public. Healthcare professionals must also inform the clinical governance leads in their organisation if they want to do the procedure.

    When open-heart surgery is not high risk, or transcatheter valve repair is suitable

    There is not enough evidence on the safety and efficacy of this procedure when surgery or transcatheter tricuspid valve repair is a suitable treatment option. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation should only be done as part of formal research in these groups.

    For everyone having the procedure

    Auditing of outcomes

    Healthcare professionals doing this procedure should collect data on safety and outcomes of the procedure. Enter details about everyone having this procedure National Institute for Cardiovascular Outcomes Research (NICOR) Transcatheter Mitral and Tricuspid Valve pregistry. Regularly review the data on outcomes and safety.

    Who should be involved with the procedure

    Patient selection should be done by a multidisciplinary team. This procedure should only be done in centres specialised in medical and interventional management of tricuspid regurgitation.

    What evidence generation and research is needed

    Healthcare professionals must collect data specifically around the safety and efficacy of this procedure. More research is needed on:

    • patient selection

    • safety outcomes including bleeding, paravalvular leak and the need for pacemaker implantation

    • longer-term outcomes.

    Why the committee made these recommendations

    There is some high-quality evidence showing the procedure reduces tricuspid regurgitation and improves quality of life in the short term, compared with medicines. But there is a risk of bleeding during and after the procedure and some people need a permanent pacemaker implanted after the procedure. There is a lack of longer-term data, which is needed because the durability of the valve replacement is unknown. For some people, open surgical tricuspid valve repair or replacement is too high risk and transcatheter techniques to repair the valve are unsuitable. For these people, transcatheter tricuspid valve implantation can be used while more evidence is generated on longer-term outcomes.

    For some people open surgical tricuspid valve repair or replacement, or transcatheter tricuspid valve repair, are suitable options. For these people, it is unclear whether the benefits of this procedure outweigh the risks. So, more research is needed in these groups.